Generic Name: cabotegravir + rilpivirine
Abbreviation: CAB LA + RPV LA
Drug Class: Single-Tablet Regimens
Company: ViiV Healthcare and Janssen Therapeutics
Approval Status: Experimental
Generic Version Available: No
Cabotegravir + rilpivirine has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.
Cabotegravir + rilpivirine is an experimental HIV medication. It contains two different types of HIV drugs: one integrase inhibitor and one non-nucleoside reverse transcriptase inhibitor (NNRTI). It is currently in Phase III clinical trials.
Cabotegravir + rilpivirine is a long-acting injectable regimen containing one approved HIV medication Edurant (rilpivirine) and one experimental HIV medication (cabotegravir).
This is a long-acting injectable regimen administered every four weeks.
Last Reviewed: September 25, 2018